A Ketamine-Based Nasal Spray Is Now an FDA-Approved Depression Treatment | WHAT REALLY HAPPENED

A Ketamine-Based Nasal Spray Is Now an FDA-Approved Depression Treatment

The U.S. Food and Drug Administration has approved the first new kind of depression treatment seen in decades, a nasal spray drug based on the sedative ketamine.

The new drug, licensed by Johnson & Johnson’s pharma division, Janssen Pharmaceuticals, isn’t ketamine exactly. It’s derived from esketamine, a chemical sibling of ketamine. It will be sold under the brand name Spravato.

For years, ketamine has been prescribed off-label via IV infusion for people struggling with severe depression and suicidal ideation, with some patients experiencing relief within hours. Importantly, these are typically patients who haven’t responded well to other treatments. The nasal spray will be approved for this same select group of patients.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA